

Gary C Starling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2336713/publications.pdf>

Version: 2024-02-01

34
papers

1,889
citations

394286

19
h-index

395590

33
g-index

34
all docs

34
docs citations

34
times ranked

2366
citing authors

#	ARTICLE	IF	CITATIONS
1	Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1841-1849.	2.0	258
2	Differential Induction of Apoptosis by Fas-Fas Ligand Interactions in Human Monocytes and Macrophages. <i>Journal of Experimental Medicine</i> , 1997, 185, 1511-1516.	4.2	242
3	CD6 ligand interactions: a paradigm for SRCR domain function?. <i>Trends in Immunology</i> , 1997, 18, 498-504.	7.5	136
4	Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule. <i>European Journal of Immunology</i> , 1995, 25, 2064-2068.	1.6	130
5	Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF- β pathways. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 61-73.	2.0	123
6	Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. <i>Atherosclerosis</i> , 2000, 152, 217-227.	0.4	93
7	The Membrane-proximal Scavenger Receptor Cysteine-rich Domain of CD6 Contains the Activated Leukocyte Cell Adhesion Molecule Binding Site. <i>Journal of Biological Chemistry</i> , 1995, 270, 18187-18190.	1.6	83
8	Constitutive Expression of Functional 4-1BB (CD137) Ligand on Carcinoma Cells. <i>Journal of Immunology</i> , 2000, 165, 2903-2910.	0.4	81
9	Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding. <i>European Journal of Immunology</i> , 1997, 27, 1469-1478.	1.6	78
10	Intercellular adhesion molecule-3 is the predominant co-stimulatory ligand for leukocyte function antigen-1 on human blood dendritic cells. <i>European Journal of Immunology</i> , 1995, 25, 2528-2532.	1.6	74
11	Identification of Amino Acid Residues Important for Ligand Binding to Fas. <i>Journal of Experimental Medicine</i> , 1997, 185, 1487-1492.	4.2	70
12	Antagonism of PDGF-D by Human Antibody CRO02 Prevents Renal Scarring in Experimental Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1054-1062.	3.0	64
13	Soluble CD137 (4-1BB) Ligand Is Released Following Leukocyte Activation and Is Found in Sera of Patients with Hematological Malignancies. <i>Journal of Immunology</i> , 2001, 167, 4059-4066.	0.4	59
14	Molecular cloning of a novel member of the immunoglobulin gene superfamily homologous to the polymeric immunoglobulin receptor. <i>European Journal of Immunology</i> , 1992, 22, 1157-1163.	1.6	58
15	Identification of purine inhibitors of phosphodiesterase 7 (PDE7). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2955-2958.	1.0	48
16	Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 1829-1833.	1.0	35
17	BTNL8, a butyrophilin-like molecule that costimulates the primary immune response. <i>Molecular Immunology</i> , 2013, 56, 819-828.	1.0	34
18	Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 315-325.	1.2	34

#	ARTICLE	IF	CITATIONS
19	Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction. <i>European Journal of Immunology</i> , 1996, 26, 738-746.	1.6	28
20	Analysis of the Ligand Binding Site in Fas (CD95) by Site-Directed Mutagenesis and Comparison with TNFR and CD40. <i>Biochemistry</i> , 1998, 37, 3723-3726.	1.2	19
21	Inhibition of in vitro and in vivo T cell responses by recombinant human Tim-1 extracellular domain proteins. <i>International Immunology</i> , 2006, 18, 473-484.	1.8	19
22	PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2013, 15, R207.	1.6	18
23	Identification of the Tumor Antigen 90K Domains Recognized by Monoclonal Antibodies SP2 and L3 and Preparation and Characterization of Novel Anti-90K Monoclonal Antibodies. <i>Biochemical and Biophysical Research Communications</i> , 1997, 232, 367-372.	1.0	16
24	Nuclear Factor κ B is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR. <i>Frontiers in Immunology</i> , 2014, 4, 505.	2.2	15
25	Serum Levels of CD137 Ligand and CD178 are Prognostic Factors for Progression of Myelodysplastic Syndrome. <i>Leukemia and Lymphoma</i> , 2004, 45, 301-308.	0.6	14
26	Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells. <i>Journal of Immunology Research</i> , 2017, 2017, 1-14.	0.9	11
27	Retinoic Acid and Vitamin E Modulate Expression and Release of CD178 in Carcinoma Cells: Consequences for Induction of Apoptosis in CD95-Sensitive Cells. <i>Experimental Cell Research</i> , 2001, 270, 248-258.	1.2	10
28	Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas Ligand (CD178) expression. <i>British Journal of Haematology</i> , 2002, 117, 76-85.	1.2	10
29	Promotion of Activated Human B Cell Apoptosis and Inhibition of Ig Production by Soluble CD95 Ligand: CD95-Based Downregulation of Ig Production Need Not Culminate in Activated B Cell Death. <i>Cellular Immunology</i> , 2000, 203, 1-11.	1.4	8
30	Biophysical and Immunological Characterization and <i>In Vivo</i> Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1298-1307.	1.9	8
31	Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model. <i>Journal of Neuroimmunology</i> , 2009, 212, 65-73.	1.1	5
32	Natural killer (NK) cell activation, cytokine production, and cytotoxicity in human PBMC/myeloma cell co-culture exposed to elotuzumab (Elo) alone or in combination with lenalidomide (Len).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8087-8087.	0.8	5
33	Hairy cell leukemia cells are relatively NK-insensitive targets. <i>Pathology</i> , 1988, 20, 361-365.	0.3	2
34	Abstract 2722: Active recruitment of immune effector cells mediates in vivo tumor growth inhibition by enavatuzumab, an antibody to human TWEAK receptor. , 2012, , .		1